



Tektuma[®] (aliskiren) – First-time generic (authorized generic)

- On March 4, 2019, [PDL BioPharma announced](#) the launch of an authorized generic version [Tektuma \(aliskiren\)](#) tablets.
 - Prasco, under an agreement with PDL's wholly owned subsidiary, Noden Pharma, carried out the launch of the authorized generic.
- Tektuma is approved for the treatment of hypertension in adults and children 6 years of age and older, to lower blood pressure.
- Aliskiren is also available as a brand fixed-dose combination tablet with hydrochlorothiazide ([Tektuma HCT[®]](#)).
 - Tektuma HCT is approved for the treatment of hypertension, in patients not adequately controlled with monotherapy or as initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals.
- Tektuma carries a boxed warning for fetal toxicity.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.